A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell engager (TCE) for autoimmune disorders in a potential $1.62 billion deal. Read More
Abbisko Therapeutics Co. Ltd. has entered a research collaboration and license agreement with Eli Lilly and Co. to discover and develop innovative medicines across multiple targets, with the aim of advancing novel drug candidates with global potential. Read More
Nuvectis Pharma Inc.’s shares climbed further after the oncology-focused biotech nabbed select rights to a late-stage complement factor B inhibitor (HSK-39297/NXP-100) and a phase I BRAF inhibitor (HSK-42360/NXP-200) from Haisco Pharmaceutical Group Co. Ltd. for $40 million up front. Read More
Corxel Pharmaceuticals Ltd.’s oral small-molecule GLP-1 receptor agonist, CX-11, met the primary endpoints in a phase II trial evaluating the candidate in obese and overweight patients in the U.S., according to top-line results. Read More
The oversubscribed $330 million series B round secured by Ollin Biosciences Inc. marks more than another large venture round in ophthalmology. It also highlights an emerging biotech financing model in which Chinese pharma companies discover and clinically validate promising drugs before handing global development to well-capitalized U.S. startups backed by blue-chip venture investors. Read More
Samsung Bioepis Co. Ltd. announced positive top-line phase I and phase III data for SB-27, a proposed biosimilar to Merck & Co. Inc.’s blockbuster immunotherapy Keytruda (pembrolizumab). Preliminary analysis of parallel-run global phase I and phase III studies demonstrated SB-27’s clinical and pharmacokinetic (PK) equivalence to the reference product, according to a company announcement. Read More
Otsuka Pharmaceutical Co. Ltd. reported another clinical study win with once-daily centanafadine, a non-stimulant compound targeting attention deficit hyperactivity disorder (ADHD). Top-line results of a dedicated phase IIIb study in patients with ADHD and comorbid anxiety found that centanafadine met the primary endpoint, defined as score improvements on the Adult Investigator Symptom Rating Scale, compared with placebo at week 8. Read More
Nature Medicine has retracted a widely publicized Chinese lung cancer study that suggested administering immunotherapy before 3 p.m. could dramatically improve survival in a decision that comes amid heightened scrutiny of research integrity and data transparency in high-impact biomedical journals. Read More
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to therapy. In a multiomics study of antidepressant-naive patients presented at the 2026 World Congress of Neuropsychopharmacology (CINP), scientists from National Taiwan University found that patients who improved after antidepressant treatment maintained a more balanced and functional microbial ecosystem, recovered beneficial metabolites, and displayed blood-based biological signals that aligned with these changes. Read More
Biopharma and med-tech happenings in Asia-Pacific, including deals and partnerships, and other news in brief: Alzinova, Apollomics, Arrotex, Astellas, Cstone, Eli Lilly, Elixirgen, Everest Medicines, Fujirebio, Haisco, Herui, Launxp, Lenz, Nippon Shinyaku, Nuvectis, Sangamo. Read More
Regulatory snapshots for biopharma and med tech in Asia-Pacific, including global submissions and approvals, and other regulatory decisions and designations: Astrazeneca, Biokin, Carsgen, China Medical System, Daiichi Sankyo, Everest Medicines, Incyte Biosciences Japan, Merz, Natera, Novo Nordisk, Reprocell, Sanofi, Sumitomo, Systimmune, Teijin, Valgen Medtech. Read More
